Anne Noonan
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Anne Noonan sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).
Anne Noonan: 2 sponsored US clinical trials, 1 recruiting.
Anne Noonan sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Stage IV Pancreatic Cancer AJCC v8, with 1 trials.
Mid-pack sponsor footprint
Anne Noonan is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.
Open and recent trials
2 total, page 1 of 1
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
NCT04115163
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
NCT04164069
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Therapeutic Areas
What is open in the Anne Noonan pipeline
1 recruiting of 2 indexed (50% open); 1 completed (50%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Stage IV Pancreatic Cancer AJCC v8 (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Anne Noonan: open-pipeline peers nationwide
Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Anne Noonan sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2 trials (± recruiting share)
- 1200 Pharma · 2 trials · 50% recruiting
- 1ST Biotherapeutics · 2 trials · 50% recruiting
- 3 Waves Wellness · 2 trials · 0% recruiting
- 3EO Health · 2 trials · 0% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 3ive Labs · 50% recruiting · 2 trials
- 60 Degrees Pharmaceuticals · 50% recruiting · 4 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
- Abcentra · 50% recruiting · 2 trials
Related
What to do with this Anne Noonan page
2 registered trials is a research-attention snapshot, not an endorsement of Anne Noonan or any single study.
- 1 of Anne Noonan's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Stage IV Pancreatic Cancer AJCC v8 is the condition Anne Noonan studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Stage IV Pancreatic Cancer AJCC v8 trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Anne Noonan pipeline card: 2 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.